Navigation Links
Sangamo BioSciences Reports Third Quarter 2013 Financial Results
Date:10/23/2013

ash, cash equivalents and marketable securities will be at least $125 million at the end of 2013, inclusive of research funding from Shire but exclusive of funds arising from any additional new collaborations or partnerships, or other new sources. 

The Company reiterates its earlier guidance as follows:

  • Revenues: Sangamo expects that revenues will be in the range of $20 to $24 million in 2013, inclusive of research funding from Shire.
  • Operating Expenses: Sangamo expects that operating expenses will be in the range of $46 to $50 million for 2013.
  • Conference CallSangamo will host a conference call today, Wednesday, October 23, 2013, at 5:00 p.m. ET, which will be open to the public.  The call will also be webcast live and can be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under "Events and Presentations" http://investor.sangamo.com/events.cfm.  A replay of the webcast will also be available for two weeks after the call. During the conference call, the company will review these results, discuss other business matters, and provide guidance with respect to the rest of 2013. 

    The conference call dial-in numbers are 877-377-7553 for domestic callers and 678-894-3968 for international callers. The passcode for the call is 79054132.  For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 8:00 p.m. ET on October 23, 2013 to 11:59 p.m. ET on October 30, 2013. The conference call replay numbers for domestic and international callers are 855-859-2056 and 404-537-3406, respectively. The conference ID number for the replay is 79054132. 

    About SangamoSangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Co
    '/>"/>

    SOURCE Sangamo BioSciences, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. Sangamo BioSciences Announces Closing Of $74.2 Million Public Offering Of Common Stock And Exercise Of Over-Allotment Option
    2. Sangamo BioSciences Proposes Public Offering Of Common Stock
    3. Biotech Firms Receive Orphan Drug Designations, Release Clinical Data, Achieve Goals, Enter Acquisitions & Forecast Revenues - Research Report on Aegerion, Oncolytics, Merrimack, Sangamo, and PDL
    4. Sangamo BioSciences Announces Presentation At The 2013 Wedbush Life Sciences Management Access Conference
    5. Sangamo BioSciences Announces Presentation at the Bank of America Merrill Lynch 2013 Health Care Conference
    6. Sangamo BioSciences Announces Presentation At The Needham Healthcare Conference
    7. Sangamo BioSciences Announces Presentation At Regen Med Investor Day
    8. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
    9. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
    10. Sangamo BioSciences Announces Presentation At The Stifel Nicolaus 2012 Healthcare Conference
    11. Sangamo BioSciences Announces Second Quarter 2012 Conference Call and Webcast
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... 24, 2014 The report expects global ... by 2019. It also provides a carefully analyzed data ... challenges for the market. , Full Copy of Report ... the global market for cell expansion will keep witnessing ... expects this growth to be driven by rapid technological ...
    (Date:12/24/2014)... AUSTIN, Texas , Dec. 23, 2014 /PRNewswire/ ... solutions company focused on gynecologic disease, announced today ... W. Schuler , Birchview Fund LLC and several ... million of unregistered shares of Vermillion,s common stock ... common stock in a private placement.  ...
    (Date:12/24/2014)... Fla. , Dec. 23, 2014  Rock Creek ... that it has filed a Clinical Trial Application (CTA) ... Healthcare products Regulatory Agency (MHRA) seeking regulatory approval to ... lead molecule, Anatabine Citrate. Contingent on the ... conduct a Phase I trial to assess the safety, ...
    (Date:12/22/2014)... 2014   Synthetic Biologics, Inc. ... therapies for serious infections and diseases, with ... announced positive topline safety and tolerability results ... SYN-004, the Company,s investigational oral beta-lactamase enzyme ... (C. difficile) infection, antibiotic-associated diarrhea and ...
    Breaking Biology Technology:The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
    ... 16 BioEnergy International, ... of next-generation, renewable biochemicals and biofuels, announces the ... all of its biobased chemicals business and intellectual ... biofuels opportunities, including its 110 million gallon per ...
    ... June 16 Wyeth (NYSE: WYE ) (the ... Senior Debentures due 2024 (the "Convertible Debentures") have the right ... to their terms effective on the July 15, 2009 purchase ... in aggregate principal amount of Convertible Debentures outstanding. , ...
    ... Wound Care Innovations, LLC, a subsidiary of Wound ... reached an agreement in principle to acquire BioPharma Management ... platform of proprietary and patented technologies for topical pain ... structured as a share exchange pursuant to which BioPharma ...
    Cached Biology Technology:BioEnergy International, LLC Announces Formation of Myriant Technologies LLC 2Wyeth Announces Holder Right to Surrender Convertible Debentures 2Wyeth Announces Holder Right to Surrender Convertible Debentures 3Wyeth Announces Holder Right to Surrender Convertible Debentures 4Wound Management Technologies, Inc. Announced Today That It Has Reached an Agreement in Principal to Acquire BioPharma Management Technologies, Inc. 2
    (Date:12/19/2014)... , Dec. 18, 2014 Research and Markets ... of the "Micro Market Monitor: North America Perimeter ... http://photos.prnewswire.com/prnh/20130307/600769 The ... at a CAGR of 3.6% from 2014 to 2019. ... this market, Canada is expected ...
    (Date:12/17/2014)... , Dec. 15, 2014 Research and ... the addition of the "Samsung Galaxy S5 ... report to their offering. ... a totally different sensing technology than the iPhone ... fingerprint sensor in its product. The ...
    (Date:12/17/2014)... 2014 Valencell, a leader in performance biometric ... to industry leaders such as Intel, Jabra, Atlas, and ... wearable products. These products will be showcased at CES ... Vegas . "Our partners choose ... robust – with the clinical data to back it ...
    Breaking Biology News(10 mins):Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
    ... recent study led by scientists from the National University of ... Spinal Muscular Atrophy (SMA), a devastating disease that is the ... young adults. As there is currently no known cure for ... fight against SMA. SMA is caused by deficiencies ...
    ... , Dec. 18, 2013 Tissue engineering ... a regenerative or reparative medicine with potential to ... engineering, which involve leveraging technologies from biomaterials, molecular ... the restructure and/or repair of human organs through ...
    ... have shown for the first time that the specialised role ... cilia tiny hair-like structures protruding from a cell. Stem ... body through the process of differentiation. The discovery ... therapies for a range of medical treatments where scientists aim ...
    Cached Biology News:Study led by NUS scientists provides new insights into cause of human neurodegenerative disease 2Study led by NUS scientists provides new insights into cause of human neurodegenerative disease 3State-of-the-Art Tissue Engineering and Organ Regeneration Technologies Yield Healthcare Market Disruption 2State-of-the-Art Tissue Engineering and Organ Regeneration Technologies Yield Healthcare Market Disruption 3State-of-the-Art Tissue Engineering and Organ Regeneration Technologies Yield Healthcare Market Disruption 4
    ...
    ... CryoMed Freezers for IVF are designed for ... control, ease of setup and operation, and ... status are continuously displayed on the control ... data are printed by way of the ...
    ... performance for all vacuum requirements. A 3 ... to suit all applications. The large, sideview ... proper oil levels at a glance. The ... work with all Thermo Savant SpeedVac concentrating ...
    A powerful, easy-to-use solution, the SORVALL RC12BP Blood Processing System allows you to manufacture blood components quickly and cost-effectively while ensuring product quality, safety, and GMP co...
    Biology Products: